Immune Checkpoint Inhibitors: all 7,814 studies that test it
Page 56 of 79. Open to participants first (2,629), then studies with results posted, then the rest; newest registration first within each.
- Camrelizumab Combined With Apatinib for Advanced Gastric or Esophagogastric AdenocarcinomaStatus unknownNCT04948125Phase 2
- The Combination of Fruquintinib, Tislelizumab and Stereotactic Ablative Radiotherapy in Metastatic Colorectal Cancer(RIFLE)Status unknownNCT04948034Phase 2
- Combination Therapy of HAIC and HLX10 and HLX04 in HCC With Major Portal Vein Tumor ThrombosisStatus unknownNCT04947826Phase 2
- Toripalimab Combined With Gemcitabine and Cisplatin Treating Resectable Locally Advanced HNSCCActive, not recruitingNCT04947241Phase 1
- Pembrolizumab and Paclitaxel in Hormone Receptor-positive, hyperMUTATted Metastatic Breast Cancer Identified by Whole exOme sequeNcing ('MUTATION2')Status unknownNCT04946227Phase 2
- IBI310 in Combination With Siltilimab in Subjects With Anti-PD-1/PD-L1 Resistance R/M NPCCompletedNCT04945421Phase 1
- GSL Synthetase Inhibitor in Combination With Immune Checkpoint Inhibitor in Previously Treated Blood and Solid TumorCompletedNCT04944888Phase 1
- PD-1 Antibody Improve Mixed ChimerismStatus unknownNCT04944511Not applicable
- SCION: SABR and Checkpoint Inhibition of NSCLCWithdrawnNCT04944173Phase 2
- Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA)WithdrawnNCT04943627Phase 3
- Study of a Pembrolizumab-based Organ Preservation Strategy for Locally Advanced Larynx CancersCompletedNCT04943445Phase 2
- Neoadjuvant Immunotherapy and Chemotherapy Followed by Surgery in Unresectable Stage Ⅲ NSCLCStatus unknownNCT04943029Phase 2
- Neoadjuvant Immunotherapy With Chemotherapy for Stage I-IIIB Non-Small Cell Lung Cancer PatientsStatus unknownNCT04941417Phase 2
- UNITO-001- Study in HRR/PDL1 Positive MPM/NSCLCStatus unknownNCT04940637Phase 2
- Neoadjuvant Safety of Sintilimab + XELOX + Bevacizumab in PMMR/MSS CRLM PatientsActive, not recruitingNCT04940546Phase 1/2
- Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial CarcinomaActive, not recruitingNCT04940299Phase 2
- Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic CancerActive, not recruitingNCT04940286Phase 2
- Window of Opportunity Study of Preoperative Immunotherapy With Atezolizumab in Local SCCHNCompletedNCT04939480Phase 2
- Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)Active, not recruitingNCT04938817Phase 1/2
- Neoadjuvant Immunoradiotherapy in Head & Neck Cancer (NIRT 2-HNC)Active, not recruitingNCT04938609Phase 2
- The Neoadjuvant Treatment of Locally Advanced Thoracic Esophageal Squamous Cell CarcinomaStatus unknownNCT04937673Phase 2
- GEN1046 Safety and PK in Subjects With Advanced Solid MalignanciesCompletedNCT04937153Phase 1
- A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ)TerminatedNCT04933227Phase 2
- A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid CancerActive, not recruitingNCT04931654Phase 1/2
- A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian TumorsActive, not recruitingNCT04931342Phase 2
- Surufatinib Combine With Immunotherapy and Chemotherapy for Second-line Treatment in Advanced Colorectal CancerStatus unknownNCT04929652Phase 1/2
- The Safety and Efficacy of Multiple-dose of JS004 in Subject With HNCCompletedNCT04929080Phase 1/2
- Therapy Adapted for High Risk and Low Risk HIV-Associated Anal CancerActive, not recruitingNCT04929028Phase 2
- Evaluation of Cytokine Biomarkers in Melanoma Patients During ImmunotherapyStatus unknownNCT04928365Phase 2
- Induction Chemotherapy Combined With Toripalimab in Locoregionally-Advanced Laryngo-Hypopharyngeal Squamous Cell CancerStatus unknownNCT04926753Phase 1
- Toripalimab Plus Sorafenib in Patients With Advanced-Stage Hepatocellular CarcinomaStatus unknownNCT04926532Phase 1/2
- A Safety Study Adding Niraparib and Dostarlimab to Radiation Therapy for Rectal CancersTerminatedNCT04926324Phase 1
- L-TIL Plus Tislelizumab as First-line Treatment in Advanced Malignant MelanomaTerminatedNCT04924413Phase 2
- Safety and Efficacy Study of Tislelizumab in Combination With BCG in HR-NMIBC Patients (TACBIN-01)Status unknownNCT04922047Phase 1/2
- Immunotherapy and Chemotherapy in Unresectable Recurrent Loco-regionally Advanced Nasopharyngeal CarcinomaStatus unknownNCT04921995Phase 2
- All-Trans Retinoic Acid (ATRA) and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung CancerCompletedNCT04919369Phase 1
- Study of IBI323 in Patients With Advanced MalignanciesStatus unknownNCT04916119Phase 1
- Tislelizumab in Combination With Eribulin for Patients With Metastatic Previously heaviLy-treAted TriplE-negative Breast Cancer：A Prospective Multiple-center Phase II StudyStatus unknownNCT04913571Phase 2
- SBRT and Durvalumab for Inoperable/Unresectable Hepatocellular CarcinomaStatus unknownNCT04913480Phase 2
- Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor MalignanciesActive, not recruitingNCT04913337Phase 1/2
- REduced Frequency ImmuNE Checkpoint Inhibition in CancersStatus unknownNCT04913025Phase 2
- IBI322 Monotherapy or Combination Therapy in Subjects With Advanced Malignant Tumors.CompletedNCT04912466Phase 1
- A Study of Dose Escalation of IBI321 in Patients With Advanced Solid TumorsCompletedNCT04911894Phase 1
- A Study of the Safety and Tolerability of IBI321 in Patients With Advanced Solid TumorsCompletedNCT04911881Phase 1
- Consolidation Nivolumab After Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal CarcinomaActive, not recruitingNCT04910347Phase 2
- Camrelizumab Plus Doxorubicin for the First Line Treatment of Adcanced Soft Tissue SarcomaStatus unknownNCT04910126Phase 2
- Chemotherapy Combined With Tislelizumab as Bladder Sparing Option for Patients With Muscle Invasive Bladder CancerStatus unknownNCT04909775Phase 2
- PD-1 Blockade Combined With De-intensified Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal CarcinomaActive, not recruitingNCT04907370Phase 3
- Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial CancerTerminatedNCT04906382Early Phase 1
- Total Neoadjuvant Treatment Plus PD-1 in Mid-Low Locally Advanced Rectal CancerActive, not recruitingNCT04906044Phase 1
- A Study of Canakinumab With Chemotherapy, Radiation Therapy, and Durvalumab in People With Lung CancerCompletedNCT04905316Phase 2
- Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell CancerTerminatedNCT04904302Phase 2
- Tislelizumab Combined With Nab-paclitaxel and Gemcitabine for Recurrent Pancreatic CancerStatus unknownNCT04902261Phase 2
- Circulating Tumour DNA guidEd Therapy for Stage IIB/C mElanoma After surgiCal resecTIONTerminatedNCT04901988Phase 2/3
- Camrelizumab Plus Apatinib as Maintenance Therapy in Extensive-stage Small-cell Lung CancerStatus unknownNCT04901754Phase 2
- A Trial of AK112 (PD-1/VEGF Bispecific Antibody) in Patients With NSCLCCompletedNCT04900363Phase 1/2
- Dexamethasone, Azacytidine,Pegaspargase and Tislelizumab for NK/T Cell LymphomaStatus unknownNCT04899414Phase 2
- A Study of Pembrolizumab and Radiation Therapy in People With MesotheliomaActive, not recruitingNCT04897022Phase 1
- Vilastobart (XTX101) Monotherapy and Vilastobart and Atezolizumab Combination Therapy in Advanced Solid TumorsCompletedNCT04896697Phase 1/2
- Lung Cancer With Copanlisib and DurvalumabCompletedNCT04895579Phase 1
- Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)Active, not recruitingNCT04895358Phase 3
- A Study of TQB2450 in Combination With Intensity-modulated Radiotherapy in Patients With Inoperable Locally Recurrent Nasopharyngeal CarcinomaCompletedNCT04895345Phase 2
- Maintenance Niraparib and Dostarlimab in Advanced CholangiocarcinomaWithdrawnNCT04895046Phase 2
- Vactosertib and Durvalumab in Gastric CancerStatus unknownNCT04893252Phase 2
- A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck CancersWithdrawnNCT04892875Phase 1
- Hypofractionated Radiotherapy Combined With PD-1 Inhibitor Sequential GM-CSF and IL-2 for the Treatment of Advanced Refractory Solid Tumors (PRaG2.0)Status unknownNCT04892498Phase 2
- EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung CancerTerminatedNCT04892472Phase 2
- TQB2450 Plus Anlotinib Combined With Chemotherapy in the Treatment of Gastric or Gastroesophageal Junction AdenocarcinomaActive, not recruitingNCT04891900Not applicable
- Tislelizumab Combined With S-1 Plus Oxaliplatin as a Neoadjuvant Treatment in Patients With GC/GEJCStatus unknownNCT04890392Phase 2
- Durvalumab (MEDI4736) and Radiosurgery (fSRT Vs. PULSAR) for the Treatment of Non-Small Cell Lung Cancer Brain MetastasesWithdrawnNCT04889066Phase 2
- Camrelizumab Plus Famitinib as Treatment in Patient With Advanced or Metastatic Pulmonary Sarcomatoid CarcinomaCompletedNCT04888429Phase 2
- Lenvatinib and Pembrolizumab Maintenance Therapy for the Treatment of Patients of Advanced Unresectable Pancreatic CancerActive, not recruitingNCT04887805Phase 2
- PK Study to Assess Drug-drug Interaction and QTc Between Sitravatinib and a Cocktail of SubstratesCompletedNCT04887194Phase 1
- Study of the SG001 Injection for Patients With Relapsed or Metastatic Uterine Cervical CancerStatus unknownNCT04886700Phase 2
- Recombinant Humanized Anti-CD47 / PD-1 Bifunctional Antibody HX009 Injection in the Treatment of Advanced Solid TumorsCompletedNCT04886271Phase 2
- An Open-label, Single Arm, Phase II Trial of Niraparib in Combination With Anti-PD1（Programmed Cell Death Protein 1） Antibody in Recurrent/ Advanced Stage Endometrial Cancer PatientsStatus unknownNCT04885413Phase 2
- Camrelizumab Combined With Radiotherapy and Chemotherapy for the Treatment of Recurrent or Metastatic Cervical CancerStatus unknownNCT04884906Phase 2
- Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)Active, not recruitingNCT04884282Phase 2
- Sintilimab and Nimotuzumab Combined With Chemotherapy for the Treatment of R/M HNSCC.Status unknownNCT04882462Phase 2
- Study to Test the Safety and Tolerability of PF-07257876 in Participants With Selected Advanced Tumors.CompletedNCT04881045Phase 1
- Afatinib Plus Toripalimab in Previously Treated ESCC With EGFR Overexpression or EGFR AmplificationStatus unknownNCT04880811Phase 2
- SBRT/LDRT in Combination With Camrelizumab and Apatinib in Metastatic Non-small Cell Lung Cancer Patient Previously Treated With PD-1/L1 Inhibitor and ChemotherapyStatus unknownNCT04878107Phase 2
- A Study of Carboplatin Plus Etoposide With or Without ZKAB001 (Anti-PD-L1 Antibody) in Patients With ES-SCLCCompletedNCT04878016Phase 3
- The Efficacy and Safety of Sintilimab Plus Anlotinib Combined With Chemotherapy as Neoadjuvant Therapy in TNBCCompletedNCT04877821Phase 2
- Cemiplimab for Secondary AngiosarcomasCompletedNCT04873375Phase 2
- A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative TherapyActive, not recruitingNCT04873362Phase 3
- Efficacy and Safety of Sintilimab Plus Bevacizumab in Metastatic Nasopharyngeal Carcinoma After Failure of Platinum-based Chemotherapy: An Open-label Phase II StudyStatus unknownNCT04872582Phase 2
- Pre-operative Immunotherapy in Stage II-III Urothelial CancerCompletedNCT04871594Phase 1
- Study of AK112 in the Treatment of Advanced Gynecological TumorsCompletedNCT04870177Phase 2
- A Study to Evaluate Subcutaneous Durvalumab in Patients With Non-Small Cell Lung Cancer and Small Cell Lung CancerTerminatedNCT04870112Phase 1
- A Study to Evaluate the Similarity in Pharmacokinetics and Safety of IBI310 and Ipilimumab（YERVOY）in Adult Healthy Chinese Male VolunteersCompletedNCT04868760Phase 1
- A Study of AK104（ an Anti-PD-1 and Anti-CTLA-4 Bispecific Antibody) in Recurrent or Metastatic Cervical CancerCompletedNCT04868708Phase 2
- A Study to Evaluate Safety, Tolerability, PK/PD and Preliminary Efficacy of HBM4003 Combined With Anti-PD-1 AntibodyStatus unknownNCT04866485Phase 1
- An Exploratory Clinical Study of SHR6390 and SHR1020 in the Treatment of Esophageal Squamous Cell Carcinoma After Progression on PD-1 AntibodyStatus unknownNCT04866381Phase 2
- Neoadjuvant Chemotherapy and Tilelizumab in Stage III（cTNM-IIIA.IIIB）Non-small-cell Lung CancerStatus unknownNCT04865705Phase 2
- QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical CancerTerminatedNCT04864782Phase 2/3
- Combination of Ipi/Nivo Plus Sacituzumab Govitecan in Metastatic Cisplatin Ineligible Urothelial Carcinoma PatientsActive, not recruitingNCT04863885Phase 1/2
- Pembrolizumab in Post Radical Operation ESCC Patients With Lymph Node Positive ( KEYSTONE-004 )Status unknownNCT04863079Phase 2
- Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and NeckActive, not recruitingNCT04862650Phase 2
- NBTXR3, Radiation Therapy, and Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell CancerTerminatedNCT04862455Phase 2